CALL/AMGEN/300/0.1/21.06.24 | Real-time BOERSE MUENCHEN 14:26:11 2024-06-20 EDT | ||
| 0.88 EUR | +23.94% |
|
| Current month | -16.47% | ||
| 1 month | -51.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 0.88 | +23.94% |
| 24-06-19 | 0.71 | +9.23% |
| 24-06-18 | 0.65 | +31.85% |
| 24-06-17 | 0.493 | +117.18% |
| 24-06-14 | 0.227 | -17.45% |
Real-time BOERSE MUENCHEN
Last update June 20, 2024 at 02:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GZ8ZXM |
| ISIN | DE000GZ8ZXM9 |
| Date issued | 2023-02-20 |
| Strike | 300 $ |
| Maturity | 2024-06-21 (1 Days) |
| Parity | 10 : 1 |
| Emission price | 0.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.41 € |
|---|---|
| Lowest since issue | 0.12 € |
| Spread | 0.05 € |
| Spread % | 5.21% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
306
USD
Average target price
316.4
USD
Spread / Average Target
+3.42%
- Stock Market
- Warrants
- Warrant
